In chronic lymphocytic leukemia (CLL), analysis of TP53 aberrations (deletion and/or
mutation) is a crucial part of treatment decision-making algorithms. Technological and …

BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies
including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom …

Background In the primary analysis report of the GAIA/CLL13 trial, we found that venetoclax–
obinutuzumab and venetoclax–obinutuzumab–ibrutinib improved undetectable measurable …

Bruton's tyrosine kinase (BTK) is involved in B-cell receptor signaling and has been clinically
validated as a target by small molecule inhibition for the treatment of a variety of cancers …

Purpose Surrogate endpoints are commonly used to estimate treatment efficacy in clinical
studies of chronic lymphocytic leukemia (CLL). This patient-and trial-level analysis describes …

Simple Summary The treatment of chronic lymphocytic leukemia is constantly evolving.
Within the past few years, the treatment algorithm of patients with CLL has been radically …

Simple Summary Chronic Lymphocytic Leukemia (CLL) is one of the most frequent leukemia
in the west countries for adult patients. It's typically a slow-growing disease and the majority …

We previously reported high rates of undetectable minimal residual disease< 10− 4
(uMRD4) with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) followed …

Therapeutic targeting of apoptosis with small molecule B-cell lymphoma 2 (BCL-2) inhibition
with venetoclax is highly efficacious in CLL, leading to sustained deep responses …

Introduction Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),
characterized by its monoclonal lymphoproliferative nature, is an indolent but incurable …